What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for a biotech blow-up?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism.
For more on what we cover, here’s the radiopharmaceuticals story; here’s the news on Lilly; here’s more on Ventyx Biosciences; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.
Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].